Transcatheter aortic-valve replacement (TAVR) showed no significant difference in primary composite outcomes compared to surgery in low-risk patients at five years.
Does Transcatheter Aortic-Valve Replacement (TAVR) improve primary composite outcomes in low-risk patients with severe, symptomatic aortic stenosis compared to surgery?
At five years, TAVR performs similarly to surgery regarding primary composite outcomes in low-risk patients with severe, symptomatic aortic stenosis.
Among low-risk patients with severe, symptomatic aortic stenosis who underwent TAVR or surgery, there was no significant between-group difference in the two primary composite outcomes. (Funded by Edwards Lifesciences; PARTNER 3 ClinicalTrials.gov number, NCT02675114.).
“[The study] provides robust, long-term evidence supporting the use of balloon-expandable TAVR in appropriately selected low-risk patients and reinforces the current guideline recommendations.”
The 5-year results of the PARTNER 3 trial, though published in late 2023, continue to be a major topic of discussion, showing no significant difference in the primary composite outcome between TAVR and surgery in low-risk patients, which has profound implications for the treatment of aortic stenosis.
Mack et al. (2023) studied this question. Transcatheter aortic-valve replacement (TAVR) showed no significant difference in primary composite outcomes compared to surgery in low-risk patients at five years.